What regulatory steps must a manufacturer follow to secure CE marking for a low-risk lateral flow device in the EU?

For a low-risk lateral flow immunoassay device, the path to CE marking is no longer a simple three-step self‑certification.
Under the current In Vitro Diagnostic Medical Devices Regulation (IVDR, EU 2017/746), which fully replaced the old IVDD from May 2022, a “Class A” device (lowest risk) still follows a self‑declaration route — but with significantly more preparatory and post‑market requirements. You must implement a quality management system, compile detailed technical documentation, appoint a European Authorized Representative, register with EUDAMED, and issue a Declaration of Conformity before affixing the CE mark.

The old IVDD’s lax, three‑step self‑certification is gone. Today, even the simplest Class A lateral flow test demands a robust, documented QMS, a Person Responsible for Regulatory Compliance, UDI registration, and ongoing post‑market surveillance — all before the CE mark can be legally applied.

Understanding the New Baseline: Class A Under the IVDR

The risk classification for lateral flow immunoassay devices has shifted.
Under the IVDR, the previous “Class 1” is now Class A — the lowest risk category, covering routine pregnancy or drug‑of‑abuse screening tests that are non‑sterile and not intended for self‑testing (which has its own classification).

Why the IVDD Route Is Obsolete

The primary reference describes a process under the IVDD, which ended in May 2022.
It mentioned compiling a technical file, appointing an Authorized Representative, and signing a Declaration of Conformity — without a mandatory QMS or the deeper scrutiny now required.
Today, that approach alone would not be legally sufficient.

What “Self‑Declaration” Actually Means Under IVDR

For Class A devices, no Notified Body is involved in the conformity assessment.
You don’t submit your technical documentation for external approval before CE marking.
But you must still establish and maintain a full quality management system covering production, post‑market surveillance, and vigilance, and you must document compliance with all applicable General Safety and Performance Requirements (GSPRs).

The Step‑by‑Step Regulatory Path Today

The modern process is a sequence of interdependent steps.
Missing one can delay market access or render the CE mark invalid.

Step 1: Build a Quality Management System (QMS)

A certified QMS is no longer optional — it is a prerequisite for drawing up the Declaration of Conformity.
Your QMS must cover design, manufacture, final inspection, storage, and post‑market activities.
While an external certification (ISO 13485) is not legally mandatory for Class A, it must be implemented and documented to meet IVDR Annex IX requirements.

Step 2: Prepare Comprehensive Technical Documentation

The old “technical file” concept is now an Annex II and III technical documentation package.
You must demonstrate that the device meets all relevant GSPRs, including:

• Analytical performance: sensitivity, specificity, accuracy, limit of detection.
• Stability and shelf‑life studies.
• Clinical evidence: a literature‑based justification or performance evaluation report for low‑risk devices.
• Risk management file (ISO 14971), including foreseeable misuse.
• Labeling and instructions for use in the required EU languages.

Step 3: Appoint a European Authorized Representative

If you are a manufacturer based outside the EU, a single Authorized Representative physically located in the Union is mandatory.
This entity will register the device in EUDAMED, act as your regulatory liaison, and keep a copy of the technical documentation.
The Representative’s name and address must appear on your label alongside the CE mark.

Step 4: Assign a Person Responsible for Regulatory Compliance (PRRC)

Every manufacturer must designate at least one qualified PRRC.
This person ensures that the technical documentation is in order, that post‑market surveillance is conducted, and that vigilance reporting obligations are fulfilled.
For small companies, this role can be subcontracted, but it cannot be left unassigned.

Step 5: Comply with UDI and Register in EUDAMED

Before placing the device on the market, you must assign a Unique Device Identifier (UDI) and upload the core data elements into the EUDAMED database.
This includes the device identifier, your company and Authorized Representative details, and the device’s risk class.
Registration must be completed before the Declaration of Conformity is signed.

Step 6: Draw Up and Sign the Declaration of Conformity

Only after the QMS is established, the technical documentation is complete, and EUDAMED registration is verified do you sign the legally binding Declaration of Conformity.
By signing, you assume full legal responsibility that the device complies with the IVDR.
The Declaration must cover all devices you intend to place on the market under that model.

Step 7: Affix the CE Mark (and Notified Body Number, If Applicable)

For a non‑sterile, non‑self‑testing Class A device, no Notified Body number accompanies the CE mark.
The mark itself can be affixed only after the Declaration of Conformity is signed.
It must be visible, legible, and indelible on the device or its packaging.

Understanding the Trade‑offs

The self‑declaration route sounds simpler than it is in practice.
The IVDR deliberately raised the bar to improve safety and traceability.

Hidden Costs and Ongoing Burdens

Even without a Notified Body audit, you must invest in:

• QMS documentation and maintenance (often as extensive as for higher‑risk classes).
• Post‑market surveillance plans and periodic safety update reports (PSURs) for Class A devices, though simplified.
• Vigilance and incident reporting to the competent authorities.
• Continuous oversight by your Authorized Representative and PRRC.

These ongoing obligations make the initial CE marking only the beginning of a permanent compliance process.

Risk of Misclassification

Some lateral flow tests that appear “low risk” — for example, tests for certain infectious diseases or tumor markers — fall into Class B or higher under IVDR.
If your intended purpose pushes the device into a higher class, the self‑declaration route disappears and a Notified Body becomes mandatory.
An early misclassification can lead to a complete restart of the regulatory submission and substantial delays.

Making the Right Choice for Your Project

The key to a smooth CE marking process is to treat the QMS and technical documentation as your primary assets — not afterthoughts.
Use these goal‑based recommendations to structure your approach:

• If your primary focus is a quick, first‑time EU market entry for a routine pregnancy or drug screening test: Start building your QMS and technical documentation simultaneously, appoint a PRRC and a reliable EU Authorized Representative early, and complete EUDAMED registration before finalising your Declaration of Conformity.
• If your primary focus is long‑term scalability, where the same platform might expand to higher‑risk indications: Design your QMS to meet full IVDR quality management standards from the start, even if it exceeds Class A requirements; this prevents expensive rework later when a Notified Body becomes necessary.
• If your primary focus is cost containment and you are considering a minimalist approach: Be aware that the IVDR’s QMS and post‑market surveillance expectations create a non‑negotiable operational baseline — cutting corners here risks product withdrawal and liability, so budget for continuous compliance, not just the initial marking.
• If your primary focus is gaining fast access to multiple EU member states: Verify your Authorized Representative’s registration capabilities across all target countries and ensure your label translations cover the languages of those states — registration in one country does not automatically register in others.

The route to CE marking for a Class A lateral flow test is now a structured, quality‑system‑driven journey. Those who embrace that rigour from day one earn the fastest, most defensible access to the European market.

Summary Table:

Streamline Your Lateral Flow Assay Development & IVDR Compliance

Navigating EU IVDR standards requires both high-performing assay components and rigorous regulatory documentation. CamelBio provides diagnostic manufacturers, labs, and research institutes with one-stop access to premium IVD raw materials, technical services, and consulting—covering every stage from concept to clinic.

Whether you need reliable antibodies, custom assay development, or guidance on technical documentation, CamelBio is here to accelerate your market entry. Contact us today to discuss your project requirements!